Key facts
- Nuclidium’s last known valuation is $163.2M (Jul 2025).
- It has raised $100.6M; the latest was Later Stage VC ($97.7M) in Jul 2025.
- Notable investors include Innosuisse, Bayern Kapital, Highlight Capital, NRW.Bank, Kurma Partners — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Nuclidium
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuclidium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuclidium
Developer of novel radiopharmaceutical tracers designed to target cancer diagnostics. The company's platform provides new diagnostic and therapeutic tracers in which specific target molecules will first be detected on the patient's tumor and can be treated with similar chemical properties and the same biological molecular targets, enabling the patients to access affordable and effective personalized treatment.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2017
- Employees
- 8
- Website
- nuclidium.com/
- Ownership
- Privately Held (backing)
Nuclidium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuclidium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuclidium in its N-PORT filings yet. We sweep new filings monthly.